Carcinoma, Squamous Cell Clinical Trials

15 recruitingLast updated: June 17, 2026

There are 15 actively recruiting carcinoma, squamous cell clinical trials across 30 countries. Studies span Phase 1, Phase 2, Not Applicable, Phase 3. Top locations include Toronto, Ontario, Canada, Los Angeles, California, United States, Boston, Massachusetts, United States. Updated daily from ClinicalTrials.gov.


Carcinoma, Squamous Cell Trials at a Glance

15 actively recruiting trials for carcinoma, squamous cell are listed on ClinicalTrialsFinder across 6 cities in 30 countries. The largest study group is Phase 1 with 5 trials, with the heaviest enrollment activity in Toronto, Los Angeles, and Boston. Lead sponsors running carcinoma, squamous cell studies include UNC Lineberger Comprehensive Cancer Center, University of Chicago, and Jiangxi Provincial Cancer Hospital.

Browse carcinoma, squamous cell trials by phase

Treatments under study

About Carcinoma, Squamous Cell Clinical Trials

Looking for clinical trials for Carcinoma, Squamous Cell? There are currently 14 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Carcinoma, Squamous Cell trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Carcinoma, Squamous Cell clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 115 of 15 trials

Recruiting
Phase 3

JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC

Carcinoma, Squamous Cell
Johnson & Johnson Enterprise Innovation Inc.500 enrolled191 locationsNCT04892173
Recruiting
Phase 1

Intralesional 5-Fluorouracil (5FU), Topical Calcipotriene Treatment for SCC

Carcinoma, Squamous Cell
Melissa Pugliano-Mauro30 enrolled1 locationNCT03370406
Recruiting
Phase 1Phase 2

Intratumoral N17350 in Advanced Solid Tumors

MelanomaCarcinoma, Non-Small Cell LungHead and Neck Neoplasms+4 more
Onchilles Pharma Inc275 enrolled1 locationNCT07339176
Recruiting

Prospective Observational Study to Validate Circulating HPVDNA and Prognostic Genomic Biomarkers in HPV-associated OPSCC

Head and Neck Squamous Cell CarcinomaCarcinoma, Squamous CellOropharyngeal Squamous Cell Carcinoma+1 more
UNC Lineberger Comprehensive Cancer Center220 enrolled3 locationsNCT04564989
Recruiting
Not Applicable

A Study on Tumor Budding Guiding Individualized Surgical Planning of Early-stage Oral Squamous Cell Carcinoma.

Carcinoma, Squamous Cell
Jinsong Hou524 enrolled1 locationNCT02743832
Recruiting
Phase 2

Lenvatinib and Pembrolizumab to Treat Patients With Anal or Rectum Cancer That Has Gotten Worse After Initial Treatment

Carcinoma, Squamous CellAnorectal Cancer
University of Chicago35 enrolled1 locationNCT06669572
Recruiting
Phase 1

A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

Esophageal CancerPancreatic CancerUrothelial Carcinoma+10 more
Pfizer310 enrolled28 locationsNCT07090499
Recruiting

Circulating Tumor DNA (ctDNA) in Locally Advanced Head and Neck Squamous Cell Carcinoma

Carcinoma, Squamous CellHead and Neck Neoplasm
UNC Lineberger Comprehensive Cancer Center50 enrolled1 locationNCT04099290
Recruiting
Phase 1

Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC

Head and Neck NeoplasmsNeoplasm MetastasisCarcinoma, Squamous Cell+3 more
University of Chicago36 enrolled1 locationNCT06912087
Recruiting
Phase 1

Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors

Colorectal, CancerSquamous Cell Carcinoma of Head and NeckHead and Neck Squamous Cell Carcinoma+8 more
Bicara Therapeutics292 enrolled20 locationsNCT04429542
Recruiting
Phase 3

Nicotinamide Chemoprevention for Keratinocyte Carcinoma in Solid Organ Transplant Recipients - Pivotal Trial

Carcinoma, Squamous CellNon-melanoma Skin CancerCarcinoma, Basal Cell+1 more
Women's College Hospital396 enrolled7 locationsNCT05955924
Recruiting
Not Applicable

TGF-β And PDL-1 Inhibition in Esophageal Squamous Cell Carcinoma Combined With Chemoradiation TheRapY

Oesophageal CancerCarcinoma, Squamous Cell
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)49 enrolled1 locationNCT04481256
Recruiting
Phase 2

Neoadjuvant Targeted Therapy in Patients With Resectable EGFR-mutated Lung Squamous Cell Carcinoma

Lung CancerCarcinoma, Squamous Cell
The First Affiliated Hospital of Guangzhou Medical University51 enrolled1 locationNCT06383728
Recruiting
Phase 2

Cyclin D1 Based TPF Induction Chemotherapy for Oral Squamous Cell Carcinoma Patients at Clinical N2 Stage

Carcinoma, Squamous CellMouth Neoplasms
Shanghai Jiao Tong University School of Medicine48 enrolled1 locationNCT02290145
Recruiting
Phase 2

Anlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma Patients

Esophageal Squamous Cell CarcinomaEsophageal NeoplasmsNeoplasms by Site+8 more
Jiangxi Provincial Cancer Hospital30 enrolled1 locationNCT05252078